Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

John Gerecitano, Carol Portlock, Craig Moskowitz, Paul Hamlin, David Straus, Andrew D. Zelenetz, Zhigang Zhang, Otilia Dumitrescu, Debra Sarasohn, Dorothy Lin, Jennifer Pappanicholaou, Barbara M. Cortelli, Ellen Neylon, Rachel Hamelers, John Wright, Owen A. O'Connor

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

Original languageEnglish (US)
Pages (from-to)652-655
Number of pages4
JournalBritish Journal of Haematology
Volume146
Issue number6
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Follicular Lymphoma
Appointments and Schedules
Disease-Free Survival
Poisons
Bortezomib

Keywords

  • Bortezomib
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Gerecitano, J., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Zelenetz, A. D., ... O'Connor, O. A. (2009). Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology, 146(6), 652-655. https://doi.org/10.1111/j.1365-2141.2009.07775.x

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. / Gerecitano, John; Portlock, Carol; Moskowitz, Craig; Hamlin, Paul; Straus, David; Zelenetz, Andrew D.; Zhang, Zhigang; Dumitrescu, Otilia; Sarasohn, Debra; Lin, Dorothy; Pappanicholaou, Jennifer; Cortelli, Barbara M.; Neylon, Ellen; Hamelers, Rachel; Wright, John; O'Connor, Owen A.

In: British Journal of Haematology, Vol. 146, No. 6, 01.12.2009, p. 652-655.

Research output: Contribution to journalArticle

Gerecitano, J, Portlock, C, Moskowitz, C, Hamlin, P, Straus, D, Zelenetz, AD, Zhang, Z, Dumitrescu, O, Sarasohn, D, Lin, D, Pappanicholaou, J, Cortelli, BM, Neylon, E, Hamelers, R, Wright, J & O'Connor, OA 2009, 'Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma', British Journal of Haematology, vol. 146, no. 6, pp. 652-655. https://doi.org/10.1111/j.1365-2141.2009.07775.x
Gerecitano, John ; Portlock, Carol ; Moskowitz, Craig ; Hamlin, Paul ; Straus, David ; Zelenetz, Andrew D. ; Zhang, Zhigang ; Dumitrescu, Otilia ; Sarasohn, Debra ; Lin, Dorothy ; Pappanicholaou, Jennifer ; Cortelli, Barbara M. ; Neylon, Ellen ; Hamelers, Rachel ; Wright, John ; O'Connor, Owen A. / Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. In: British Journal of Haematology. 2009 ; Vol. 146, No. 6. pp. 652-655.
@article{99eddf4c89604deb87daeb5c40919182,
title = "Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma",
abstract = "Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18{\%} vs. 50{\%}, P = 0.02) with no complete remissions (CR) (compared with 18{\%} CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.",
keywords = "Bortezomib, Follicular lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma, Proteasome inhibitor",
author = "John Gerecitano and Carol Portlock and Craig Moskowitz and Paul Hamlin and David Straus and Zelenetz, {Andrew D.} and Zhigang Zhang and Otilia Dumitrescu and Debra Sarasohn and Dorothy Lin and Jennifer Pappanicholaou and Cortelli, {Barbara M.} and Ellen Neylon and Rachel Hamelers and John Wright and O'Connor, {Owen A.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1111/j.1365-2141.2009.07775.x",
language = "English (US)",
volume = "146",
pages = "652--655",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

AU - Gerecitano, John

AU - Portlock, Carol

AU - Moskowitz, Craig

AU - Hamlin, Paul

AU - Straus, David

AU - Zelenetz, Andrew D.

AU - Zhang, Zhigang

AU - Dumitrescu, Otilia

AU - Sarasohn, Debra

AU - Lin, Dorothy

AU - Pappanicholaou, Jennifer

AU - Cortelli, Barbara M.

AU - Neylon, Ellen

AU - Hamelers, Rachel

AU - Wright, John

AU - O'Connor, Owen A.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

AB - Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

KW - Bortezomib

KW - Follicular lymphoma

KW - Mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - Proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=68949093334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949093334&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07775.x

DO - 10.1111/j.1365-2141.2009.07775.x

M3 - Article

C2 - 19624539

AN - SCOPUS:68949093334

VL - 146

SP - 652

EP - 655

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -